Niall M Corcoran

List of Publications by Year
in descending order

77	2,901	218592	175177
papers	citations	26 h-index	52 g-index

77	77	77	5687
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The impact of multidisciplinary team meetings on patient assessment, management and outcomes in oncology settings: A systematic review of the literature. Cancer Treatment Reviews, 2016, 42, 56-72.	3.4	432
2	Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer. Nature Communications, 2015, 6, 6605.	5.8	312
3	Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer. European Urology, 2019, 76, 89-97.	0.9	158
4	Preservation of the Neurovascular Bundles Is Associated with Improved Time to Continence After Radical Prostatectomy But Not Long-term Continence Rates: Results of a Systematic Review and Meta-analysis. European Urology, 2015, 68, 692-704.	0.9	144
5	Sodium selenate specifically activates PP2A phosphatase, dephosphorylates tau and reverses memory deficits in an Alzheimerâ€™s disease model. Journal of Clinical Neuroscience, 2010, 17, 1025-1033.	0.8	134
6	Upgrade in Gleason score between prostate biopsies and pathology following radical prostatectomy significantly impacts upon the risk of biochemical recurrence. BJU International, 2011, 108, E202-E210.	1.3	103
7	Sodium selenate retards epileptogenesis in acquired epilepsy models reversing changes in protein phosphatase 2A and hyperphosphorylated tau. Brain, 2016, 139, 1919-1938.	3.7	100
8	Inorganic Selenium Retards Progression of Experimental Hormone Refractory Prostate Cancer. Journal of Urology, 2004, 171, 907-910.	0.2	90
9	MTOR signaling orchestrates stress-induced mutagenesis, facilitating adaptive evolution in cancer. Science, 2020, 368, 1127-1131.	6.0	83
10	A urinary microRNA signature can predict the presence of bladder urothelial carcinoma in patients undergoing surveillance. British Journal of Cancer, 2016, 114, 454-462.	2.9	78
11	Targeting hyperphosphorylated tau with sodium selenate suppresses seizures in rodent models. Neurobiology of Disease, 2012, 45, 897-901.	2.1	70
12	Supranutritional Sodium Selenate Supplementation Delivers Selenium to the Central Nervous System: Results from a Randomized Controlled Pilot Trial in Alzheimer's Disease. Neurotherapeutics, 2019, 16, 192-202.	2.1	69
13	Underestimation of Gleason score at prostate biopsy reflects sampling error in lower volume tumours. BJU International, 2012, 109, 660-664.	1.3	66
14	The ability of prostateâ€specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume. BJU International, 2012, 110, 36-42.	1.3	61
15	Prostate cancer cellâ€intrinsic interferon signaling regulates dormancy and metastatic outgrowth in bone. EMBO Reports, 2020, 21, e50162.	2.0	58
16	Modulation of paracrine signaling by CD9 positive small extracellular vesicles mediates cellular growth of androgen deprived prostate cancer. Oncotarget, 2017, 8, 52237-52255.	0.8	55
17	A Phase IIa Randomized Control Trial ofÂVEL015 (Sodium Selenate) inÂMild-Moderate Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2016, 54, 223-232.	1.2	53
18	Open-label, phase I dose-escalation study of sodium selenate, a novel activator of PP2A, in patients with castration-resistant prostate cancer. British Journal of Cancer, 2010, 103, 462-468.	2.9	48

#	Article	IF	Citations
19	Curated MicroRNAs in Urine and Blood Fail to Validate as Predictive Biomarkers for High-Risk Prostate Cancer. PLoS ONE, 2014, 9, e91729.	1.1	43
20	Canonical Androstenedione Reduction Is the Predominant Source of Signaling Androgens in Hormone-Refractory Prostate Cancer. Clinical Cancer Research, 2014, 20, 5547-5557.	3.2	43
21	Gene-based urinary biomarkers for bladder cancer: An unfulfilled promise?. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 48.e9-48.e17.	0.8	38
22	Detection of ctDNA in plasma of patients with clinically localised prostate cancer is associated with rapid disease progression. Genome Medicine, 2020, 12, 72.	3.6	35
23	How Subclonal Modeling Is Changing the Metastatic Paradigm. Clinical Cancer Research, 2017, 23, 630-635.	3.2	34
24	Androgen synthesis in prostate cancer: do all roads lead to Rome?. Nature Reviews Urology, 2017, 14, 49-58.	1.9	34
25	Inferring structural variant cancer cell fraction. Nature Communications, 2020, 11, 730.	5.8	33
26	Cell quiescence correlates with enhanced glioblastoma cell invasion and cytotoxic resistance. Experimental Cell Research, 2019, 374, 353-364.	1.2	31
27	Positive surgical margins are a risk factor for significant biochemical recurrence only in intermediateâ€risk disease. BJU International, 2012, 110, 821-827.	1.3	28
28	Molecular Pathways: Targeting DNA Repair Pathway Defects Enriched in Metastasis. Clinical Cancer Research, 2016, 22, 3132-3137.	3.2	28
29	Prostate tumour volume is an independent predictor of early biochemical recurrence in a high risk radical prostatectomy subgroup. Pathology, 2011, 43, 138-142.	0.3	26
30	What Is Oligometastatic Prostate Cancer?. European Urology Focus, 2019, 5, 159-161.	1.6	24
31	Extracellular vesicles for personalized therapy decision support in advanced metastatic cancers and its potential impact for prostate cancer. Prostate, 2017, 77, 1416-1423.	1.2	22
32	Does perineural invasion in a radical prostatectomy specimen predict biochemical recurrence in men with prostate cancer?. Canadian Urological Association Journal, 2015, 9, 252.	0.3	21
33	Feasibility for active surveillance in biopsy Gleason 3Â+Â4 prostate cancer: an Australian radical prostatectomy cohort. BJU International, 2016, 117, 82-87.	1.3	21
34	Comparing nodal versus bony metastatic spread using tumour phylogenies. Scientific Reports, 2016, 6, 33918.	1.6	19
35	Periprostatic fat tissue transcriptome reveals a signature diagnostic for high-risk prostate cancer. Endocrine-Related Cancer, 2018, 25, 569-581.	1.6	19
36	A review of simulation training and new 3D computer-generated synthetic organs for robotic surgery education. Journal of Robotic Surgery, 2022, 16, 749-763.	1.0	19

#	Article	IF	Citations
37	Presence or absence of a positive pathological margin outperforms any other marginâ€associated variable in predicting clinically relevant biochemical recurrence in <scp>G</scp>leason 7 prostate cancer. BJU International, 2013, 111, 921-927.	1.3	17
38	Androgen deprivation therapy promotes an obesity-like microenvironment in periprostatic fat. Endocrine Connections, 2019, 8, 547-558.	0.8	16
39	Routinely reported â€˜equivocalâ€™ lymphovascular invasion in prostatectomy specimens is associated with adverse outcomes. BJU International, 2017, 119, 567-572.	1.3	15
40	Targeted therapy in prostate cancer. Histopathology, 2012, 60, 216-231.	1.6	14
41	Roboticâ€assisted radical cystectomy with intracorporeal urinary diversion versus open: early Australian experience. ANZ Journal of Surgery, 2018, 88, 1028-1032.	0.3	14
42	Use of prostateâ€specific membrane antigen positronâ€emission tomography/CT in response assessment following upfront chemohormonal therapy in metastatic prostate cancer. BJU International, 2020, 126, 433-435.	1.3	13
43	Ductal variant prostate carcinoma is associated with a significantly shorter metastasis-free survival. European Journal of Cancer, 2021, 148, 440-450.	1.3	13
44	Microscopic assessment of fresh prostate tumour specimens yields significantly increased rates of correctly annotated samples for downstream analysis. Pathology, 2012, 44, 204-208.	0.3	12
45	Reduction in expression of the benign AR transcriptome is a hallmark of localised prostate cancer progression. Oncotarget, 2016, 7, 31384-31392.	0.8	11
46	Genetic factors associated with prostate cancer conversion from active surveillance to treatment. Human Genetics and Genomics Advances, 2022, 3, 100070.	1.0	10
47	Stimulation of the Neurovascular Bundle Results in Rhabdosphincter Contraction in a Proportion of Men Undergoing Radical Prostatectomy. Urology, 2016, 87, 133-139.	0.5	9
48	Loss of SNAI2 in Prostate Cancer Correlates With Clinical Response to Androgen Deprivation Therapy. JCO Precision Oncology, 2021, 5, 1048-1059.	1.5	9
49	Protocol for CAMUS Delphi Study: A Consensus on Comprehensive Reporting and Grading of Complications After Urological Surgery. European Urology Focus, 2022, 8, 1493-1511.	1.6	9
50	Combined low-dose imatinib mesylate and paclitaxel lack synergy in an experimental model of extra-osseous hormone-refractory prostate cancer. BJU International, 2005, 96, 640-646.	1.3	8
51	Interfering with cell-survival signalling as a treatment strategy for prostate cancer. BJU International, 2006, 97, 1149-1153.	1.3	8
52	Prostatic nerve subtypes independently predict biochemical recurrence in prostate cancer. Journal of Clinical Neuroscience, 2019, 63, 213-219.	0.8	8
53	3D modelling of radical prostatectomy specimens: Developing a method to quantify tumor morphometry for prostate cancer risk prediction. Pathology Research and Practice, 2017, 213, 1523-1529.	1.0	7
54	Unilateral testicular mass in man with chronic myelomonocytic leukemia: Unusual presentation of chronic myelomonocytic leukemia sequela. Urology, 2005, 65, 1001.	0.5	6

#	Article	IF	Citations
55	High-resolution Map of Somatic Periprostatic Nerves. Urology, 2016, 97, 160-165.	0.5	6
56	Lessons Learned and New Challenges: Re-evaluation of End-User Assessment of a Skills-Based Training Program for Urology Trainees. Journal of Medical Education and Curricular Development, 2019, 6, 238212051983455.	0.7	6
57	Late biochemical recurrence after radical prostatectomy is associated with a slower rate of progression. BJU International, 2019, 123, 976-984.	1.3	6
58	Lessons learned: end-user assessment of a skills laboratory based training programme for urology trainees. BJU International, 2011, 107, 47-51.	1.3	5
59	Bone Turnover Markers and Prostate Cancer: Not Just a Measure of Bone Disease?. European Urology, 2015, 68, 51-52.	0.9	5
60	Obesity suppresses tumor attributable PSA, affecting risk categorization. Endocrine-Related Cancer, 2018, 25, 561-568.	1.6	5
61	Developments in oligometastatic hormone-sensitive prostate cancer. World Journal of Urology, 2019, 37, 2549-2555.	1.2	5
62	MSH2-deficient prostate tumours have a distinct immune response and clinical outcome compared to MSH2-deficient colorectal or endometrial cancer. Prostate Cancer and Prostatic Diseases, 2021, 24, 1167-1180.	2.0	4
63	Lifetime Health and Economic Outcomes of Active Surveillance, Radical Prostatectomy, and Radiotherapy for Favorable-Risk Localized Prostate Cancer. Value in Health, 2021, 24, 1737-1745.	0.1	4
64	Advances in prostate cancer. Australian Journal of General Practice, 2020, 49, 200-205.	0.3	4
65	A modified Delphi study to develop a practical guide for selecting patients with prostate cancer for active surveillance. BMC Urology, 2021, 21, 18.	0.6	3
66	Transcriptome sequencing and multi-plex imaging of prostate cancer microenvironment reveals a dominant role for monocytic cells in progression. BMC Cancer, 2021, 21, 846.	1.1	3
67	The Prostate Cancer Immune Microenvironment, Biomarkers and Therapeutic Intervention. Uro, 2022, 2, 74-92.	0.3	3
68	Disrupting the Status Quo in Prostate Cancer Diagnosis. European Urology, 2017, 71, 193-194.	0.9	2
69	The modified International Society of Urological Pathology system improves concordance between biopsy and prostatectomy tumour grade. BJU International, 2021, , .	1.3	2
70	Molecular classification of hormoneâ€sensitive and castrationâ€resistant prostate cancer, using nonnegative matrix factorization molecular subtyping of primary and metastatic specimens. Prostate, 2022, 82, 993-1002.	1.2	2
71	Active involvement of nursing staff in reporting and grading complicationâ€intervention eventsâ€"Protocol and results of the CAMUS Pilot Nurse Delphi Study. BJUI Compass, 2022, 3, 466-483.	0.7	2
72	Androstenedione Is the Preferred Androgen Source in Hormone Refractory Prostate Cancerâ€"Response. Clinical Cancer Research, 2014, 20, 4972-4973.	3.2	1

#	Article	IF	Citations
73	Prostate cancer multidisciplinary care: improving patient outcomes. Trends in Urology & Men's Health, 2015, 6, 18-20.	0.2	1
74	A Historical Perspective of the Evolution of Laparoscopic Surgeries in Urology. Journal of Endourology, 2022, 36, 1277-1284.	1.1	1
75	Preparation of fluorescent in situ hybridisation probes without the need for optimisation of fragmentation. MethodsX, 2019, 6, 22-34.	0.7	0
76	New Histopathological & Genetic Features to Improve Active Surveillance Selection for Low-Risk Prostate Cancer. Anti-Cancer Agents in Medicinal Chemistry, 2018, 18, 951-957.	0.9	0
77	Biomarkers of Response to Neoadjuvant Androgen Deprivation in Localised Prostate Cancer. Cancers, 2022, 14, 166.	1.7	0